Cassava Sciences announced Thursday that federal investigators have wrapped up their examination of the company following accusations of research misconduct related to its experimental Alzheimer’s treatment, simufilam.
The biotechnology firm revealed that the Department of Justice concluded its investigation four months following the dismissal of criminal charges in Maryland against Hoau-Yan Wang, a medical professor and former company consultant. Wang had been accused of providing fraudulent data concerning the Alzheimer’s drug.
The closure of the federal investigation marks the end of scrutiny that had surrounded the company’s research practices and the development of its potential Alzheimer’s therapy.
